Although the European Medicines Agency recommended approval for Moderna's first combined flu and COVID-19 vaccine mCOMBRIAX, Moderna's stock price still fluctuated, closing at $51.06, down 1.27%. This historic approval recommendation was based on positive Phase 3 clinical trial data, but the stock price briefly surged afterward before falling back, reflecting investors' ongoing concerns about the company's profitability prospects.